한빛사311건

• • 응우엔(성균관대학교)

  • 윤유석(성균관대학교)

  STING-activating dendritic cell-targeted nanovaccines that evoke potent antigen cross-presentation for cancer immunotherapy

  • Bioact. Mater. Available online 6 September 2024; 42,345?365 | https://doi.org/10.1016/j.bioactmat.2024.09.002

  • 2024.09
  • 바이오·의료융합

• • 오유미(서울대학교 의과대학)

  • 김수정(광주과학기술원)

  • 김윤재(광주과학기술원)

  • 김현(광주과학기술원)

  • 박한수(광주과학기술원, 지놈앤컴퍼니)

  • 조성엽(서울대학교 의과대학)

  Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy

  • Mol. Cancer Aug 02 2024, 23 (1) 155 | https://doi.org/10.1186/s12943-024-02068-x

  • 2024.08
  • 의약학

• • Qihang Ding(고려대학교)

  • 김종승(고려대학교)

  An ATP-responsive metal-organic framework against periodontitis via synergistic ion-interference-mediated pyroptosis

  • Natl. Sci. Rev. Aug 2024, 11 (8) nwae225 | https://doi.org/10.1093/nsr/nwae225

  • 2024.08

• • 문석준(한양대학교)

  • 조은이(한양대학교)

  • 길우진(한양대학교)

  • 양철수(한양대학교)

  Dual alarmin-receptor-specific targeting peptide systems for treatment of sepsis

  • Acta Pharm. Sin. B Available online 19 August 2024 | https://doi.org/10.1016/j.apsb.2024.08.015

  • 2024.08
  • 생명과학

• • 최재혁(Northwestern University)

  Pre-existing skin-resident CD8 and gd T cell circuits mediate immune response in Merkel cell carcinoma and predict immunotherapy efficacy

  • Cancer Discov. Jul 26 2024, | https://doi.org/10.1158/2159-8290.CD-23-0798

  • 2024.07

• • 김재현(한양대학교)

    Interview

  • 김용희(한양대학교)

  Dual Adjuvant-Loaded Peptide Antigen Self-Assembly Potentiates Dendritic Cell-Mediated Tumor Immunotherapy

  • Adv. Sci. Jul 29 2024, | https://doi.org/10.1002/advs.202403663

  • 2024.07
  • 생명과학

• • 장선미(한양대학교)

    Interview

  • 이재빈(한양대학교)

  • 이준석(한양대학교)

  • 이동윤(한양대학교)

  Biocompatible and nondegradable microcapsules using an ethylamine-bridged EGCG dimer for successful therapeutic cell transplantation

  • J. Control. Release Jul 26 2024, 373 S0168-3659(24)00508-X | https://doi.org/10.1016/j.jconrel.2024.07.053

  • 2024.07
  • 바이오·의료융합

• • 김서영(한국과학기술연구원)

  • 김성찬(한국과학기술연구원)

  • 김현경(고려대학교 의과대학)

  • 이효진(한국과학기술연구원)

  Improvement of Therapeutic Effect via Inducing Non-Apoptotic Cell Death Using mRNA-Protection Nanocage

  • Adv. Healthc. Mater. Jul 31 2024, | https://doi.org/10.1002/adhm.202400240

  • 2024.07
  • 바이오·의료융합

• • 최윤정(시프트바이오, 고려대학교)

  • 김성아(고려대학교, 한국과학기술연구원)

  • 남기훈(시프트바이오, 고려대학교)

  • 권민수(울산대학교 의과대학)

  • 김인산(고려대학교, 한국과학기술연구원)

  Novel insights into paclitaxel‘s role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment

  • J. Immunother. Cancer Jul 15 2024, 12 (7) e008864 | https://jitc.bmj.com/content/12/7/e008864

  • 2024.07
  • 의약학

• • 김소정(울산대학교 의과대학, 서울아산병원)

  • 이창환(울산대학교 의과대학, 서울아산병원)

  • 진준오(울산대학교 의과대학, 서울아산병원)

  Lipid-coated gold nanorods for photoimmunotherapy of primary breast cancer and the prevention of metastasis

  • J. Control. Release Jul 12 2024, 373 S0168-3659(24)00451-6 | https://doi.org/10.1016/j.jconrel.2024.07.020

  • 2024.07
  • 의약학

• • 전흥진(충남대학교)

  • 임대진(강원대학교 의생명과학대학 의생명융합학부)

  • 정재호(전남대학교 의과대학)

  • 송미령(한국외국어대학교)

  • 이효진(충남대학교 의과대학, 충남대학교병원)

  Controlling tumor progression and recurrence in mice through combined treatment with a PD-L1 inhibitor and a designer Salmonella strain that delivers

  • Acta Pharm. Sin. B Available online 10 July 2024 | https://doi.org/10.1016/j.apsb.2024.07.011

  • 2024.07
  • 의약학

• • 정영록(Tessa Therapeutic)

  Overexpression of an Engineered SerpinB9 Enhances Allogeneic T-Cell Persistence and Efficacy

  • Cancer Immunol. Res. 2024 Jun 4 | https://doi.org/10.1158/2326-6066.CIR-23-1001

  • 2024.06

• • 최우선(울산대학교 의과대학)

  • 권형준(울산대학교 의과대학, 현 GSK plc)

  • 성창옥(울산대학교 의과대학, 서울아산병원)

  • 김헌식(울산대학교 의과대학)

  HPK1 Dysregulation-Associated NK Cell Dysfunction and Defective Expansion Promotes Metastatic Melanoma Progression

  • Adv. Sci. 2024 Jun 3:e2400920 | https://doi.org/10.1002/advs.202400920

  • 2024.06
  • 의약학

• • 이대훈(경희대학교 약학대학, 큐리진)

  • 최진우(경희대학교 약학대학)

  Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment

  • J. Exp. Clin. Cancer Res. Jun 18 2024, 43 (1) | https://doi.org/10.1186/s13046-024-03088-7

  • 2024.06

• • 노민혜(The University of Texas Health Science Center at Houston)

  • 강진묵(University Hospitals Cleveland Medical Center)

  • 이태진(University of Texas Health Science Center at Houston)

  • 유지영(University of Texas Health Science Center at Houston)

  Targeting IGF2-IGF1R Signaling to Reprogram the Tumor Microenvironment for Enhanced Viro-Immunotherapy

  • Neuro-Oncology Jun 10 2024, noae105 | https://doi.org/10.1093/neuonc/noae105

  • 2024.06

• • 박태윤(Harvard Medical School/McLean Hospital)

  • 김광수(Harvard Medical School)

  Past, present, and future of cell replacement therapy for parkinson‘s disease: a novel emphasis on host immune responses

  • Cell Res. May 22 2024, | https://doi.org/10.1038/s41422-024-00971-y

  • 2024.05
  • 생명과학

• • 박소영(성균관대학교)

  • 진승모(성균관대학교)

  • 임용택(성균관대학교)

  Bioconjugated Antibody-Trojan Immune Converter Enhance Cancer Immunotherapy with Minimized Toxicity by Programmed Two-Step Immunomodulation of Myeloid

  • Adv. Healthc. Mater. May 21 2024, | https://doi.org/10.1002/adhm.202401270

  • 2024.05
  • 바이오·의료융합

• • 박성진(서울대학교)

  • 박진우(목포대학교)

  • 변영로(서울대학교)

  Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway

  • Biomaterials May 25 2024, 310 S0142-9612(24)00159-5 | https://doi.org/10.1016/j.biomaterials.2024.122625

  • 2024.05
  • 생명과학

• • 김형식(Harvard Medical School)

  A non-lipid nucleic acid delivery vector with dendritic cell tropism and stimulation

  • Theranostics 2024.05.05; 14(7): 2934-2945 | https://www.thno.org/v14p2934

  • 2024.05
  • 바이오·의료융합

• • 한준혁(성균관대학교)

  • 서희승(성균관대학교)

  • 이지영(Zhejiang University)

  • 박천권(성균관대학교)

  • 박우람(성균관대학교)

  An electro-ferroptotic nanoammunition enables image-guided, spatiotemporally controlled cancer ferroptosis induction via irreversible electroporation

  • Chem. Eng. J. Volume 487, 1 May 2024, 150366 | https://doi.org/10.1016/j.cej.2024.150366

  • 2024.05
  • 바이오·의료융합